The investigation of AT7519 (CDK inhibitor) and AT13387 (HSP90 inhibitor) as novel therapies for the treatment of pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is usually a systemic disease and so requires chemotherapy even when surgical resection is possible. Current agents such as gemcitabine are only effective in a minority of patients and chemoresistance is an important issue faced in pancreatic cance...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Liverpool
2016
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.706966 |